Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
Holstein et al., 1996 - Google Patents
[go: Go Back, main page]

Holstein et al., 1996 - Google Patents

Salvage Chemotherapy with Dacarbazine or Carboplatin/VP-16 of Advanced Soft Tissue Sarcoma Pre-treated with Doxorubicin/lfosfamide

Holstein et al., 1996

Document ID
8222953500460240048
Author
Holstein K
Weh H
Walter T
Hossfeld D
Publication year
Publication venue
Oncology Research and Treatment

External Links

Snippet

Background: Doxorubicin and ifosfamide are the most active drugs in the treatment of adult advanced soft tissue sarcoma. For patients not or no longer responding to these cytostatic agents no widely accepted salvage chemotherapy is known. Patients and Methods …
Continue reading at karger.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Similar Documents

Publication Publication Date Title
Borkowski et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data
Ansfield et al. Phase I-II studies of oral tegafur (ftorafur).
Holstein et al. Salvage Chemotherapy with Dacarbazine or Carboplatin/VP-16 of Advanced Soft Tissue Sarcoma Pre-treated with Doxorubicin/lfosfamide
Gore et al. Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide
McLaughlin et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma
Souhami et al. Phase II study of edatrexate in stage III and IV non-small-cell lung cancer
Uyeki Effects of several antitumour agents on spleen hemolysin plaque-forming cells
Bishop et al. A PHASE Ml STUDY OF CYTOSINE ARABINOSIDE, DAUNORUBICIN, AND VP16–213 IN ADULT PATIENTS WITH ACUTE NON‐LYMPHOCYTIC LEUKEMIA
Mulder et al. Schedule-dependent cytotoxicity of 5-fluorouracil and cyclophosphamide in experimental cancer chemotherapy
Higano et al. Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial
Benz et al. Use of High-Dose Oral Methotrexate Sequenced at 24 Hours With 5-FU: A Clinical Toxicity Study 1, 2
Budd et al. Clinical effects of amifostine (Ethyol®) in patients treated with carboplatin
Mandelli et al. Vindesine in the treatment of refractory hematologic malignancies: A phase II study
Dimopoulos et al. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group
Plaxe et al. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix–A Gynecologic Oncology Group Study
Taylor et al. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors: A Southwest Oncology Group Trial
Harada et al. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes
Mills et al. Phase II evaluation of bisantrene in acute leukemia: a southwest oncology group study
Weh et al. Treatment of adult metastatic soft-tissue sarcoma with doxorubicin/ifosfamide: Better hematologic tolerance by G-CSF?
Serrone et al. Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules
Pazdur et al. Aclacinomycin A Phase II Evaluation in Advanced Soft Tissue Sarcoma
Vredenburgh et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia
Merlin et al. In vitro combination of high dose busulfan with radiotherapy on medulloblastoma cells: additive effect without potentiation
Vogler Clinical trials of 1‐β‐D‐arabinofuranosyl cytosine and 1, 3‐bis‐(2‐chloroethyl)‐1‐nitrosourea combination in metastatic cancer and acute leukemia
Ettinger Pemetrexed (Alimta®): A New Antifolate for non—small-Cell Lung Cancer